Mainz Biomed (MYNZ) Competitors $1.84 +0.02 (+1.10%) Closing price 04:00 PM EasternExtended Trading$1.89 +0.05 (+2.77%) As of 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock MYNZ vs. LGVN, CING, BLRX, PRPH, MRKR, RVPH, MTEX, LPCN, QTTB, and CARMShould you be buying Mainz Biomed stock or one of its competitors? The main competitors of Mainz Biomed include Longeveron (LGVN), Cingulate (CING), BioLineRx (BLRX), ProPhase Labs (PRPH), Marker Therapeutics (MRKR), Reviva Pharmaceuticals (RVPH), Mannatech (MTEX), Lipocine (LPCN), Q32 Bio (QTTB), and Carisma Therapeutics (CARM). These companies are all part of the "pharmaceutical products" industry. Mainz Biomed vs. Its Competitors Longeveron Cingulate BioLineRx ProPhase Labs Marker Therapeutics Reviva Pharmaceuticals Mannatech Lipocine Q32 Bio Carisma Therapeutics Longeveron (NASDAQ:LGVN) and Mainz Biomed (NASDAQ:MYNZ) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, dividends, analyst recommendations, institutional ownership, media sentiment, valuation, earnings and profitability. Does the media refer more to LGVN or MYNZ? In the previous week, Mainz Biomed had 2 more articles in the media than Longeveron. MarketBeat recorded 2 mentions for Mainz Biomed and 0 mentions for Longeveron. Longeveron's average media sentiment score of 0.87 beat Mainz Biomed's score of -0.02 indicating that Longeveron is being referred to more favorably in the media. Company Overall Sentiment Longeveron Positive Mainz Biomed Neutral Which has preferable earnings & valuation, LGVN or MYNZ? Longeveron has higher revenue and earnings than Mainz Biomed. Longeveron is trading at a lower price-to-earnings ratio than Mainz Biomed, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLongeveron$2.39M9.62-$15.97M-$6.28-0.25Mainz Biomed$890K7.11-$21.65M-$65.60-0.03 Which has more volatility and risk, LGVN or MYNZ? Longeveron has a beta of 0.21, indicating that its stock price is 79% less volatile than the S&P 500. Comparatively, Mainz Biomed has a beta of 0.21, indicating that its stock price is 79% less volatile than the S&P 500. Is LGVN or MYNZ more profitable? Mainz Biomed has a net margin of 0.00% compared to Longeveron's net margin of -760.72%. Mainz Biomed's return on equity of 0.00% beat Longeveron's return on equity.Company Net Margins Return on Equity Return on Assets Longeveron-760.72% -85.07% -70.74% Mainz Biomed N/A N/A N/A Do analysts prefer LGVN or MYNZ? Longeveron currently has a consensus price target of $8.67, indicating a potential upside of 462.77%. Mainz Biomed has a consensus price target of $14.00, indicating a potential upside of 660.87%. Given Mainz Biomed's higher possible upside, analysts plainly believe Mainz Biomed is more favorable than Longeveron.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Longeveron 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.25Mainz Biomed 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50 Do insiders and institutionals have more ownership in LGVN or MYNZ? 10.0% of Longeveron shares are held by institutional investors. 11.2% of Longeveron shares are held by company insiders. Comparatively, 18.2% of Mainz Biomed shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. SummaryLongeveron beats Mainz Biomed on 9 of the 16 factors compared between the two stocks. Get Mainz Biomed News Delivered to You Automatically Sign up to receive the latest news and ratings for MYNZ and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MYNZ and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MYNZ vs. The Competition Export to ExcelMetricMainz BiomedMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$6.26M$2.94B$5.57B$9.35BDividend YieldN/A2.45%3.80%4.06%P/E Ratio-0.0320.1528.0719.86Price / Sales7.11302.32441.4199.96Price / CashN/A43.1635.8457.94Price / Book0.707.838.265.67Net Income-$21.65M-$55.11M$3.24B$257.80M7 Day Performance-8.00%2.18%0.51%1.07%1 Month Performance16.46%12.98%7.99%11.31%1 Year Performance-89.16%1.98%28.68%17.01% Mainz Biomed Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MYNZMainz Biomed2.2082 of 5 stars$1.84+1.1%$14.00+660.9%-89.4%$6.26M$890K-0.0330LGVNLongeveron3.1871 of 5 stars$1.29-1.5%$8.67+571.8%-58.5%$19.26M$2.39M-0.2120CINGCingulate2.9557 of 5 stars$4.42+3.3%$26.00+488.2%+1,276.5%$18.79MN/A-0.5220BLRXBioLineRx2.4966 of 5 stars$4.32-3.8%$26.00+501.9%-85.9%$18.40M$28.94M-0.4940PRPHProPhase Labs0.5297 of 5 stars$0.44+5.6%N/A-88.7%$18.37M$6.77M-0.35130Positive NewsMRKRMarker Therapeutics4.3328 of 5 stars$1.57-1.9%$13.17+738.6%-72.6%$17.76M$6.59M-1.1860Gap UpTrading HaltedRVPHReviva Pharmaceuticals3.3873 of 5 stars$0.37+1.9%$9.00+2,353.0%-68.0%$17.61MN/A-0.465Positive NewsGap UpMTEXMannatech1.2232 of 5 stars$8.90-3.8%N/A+13.9%$16.91M$117.87M-89.00250High Trading VolumeLPCNLipocine3.0569 of 5 stars$3.11+0.3%$9.00+189.4%-54.1%$16.64M$11.20M-3.0510QTTBQ32 Bio2.7192 of 5 stars$1.36-5.6%$12.17+794.6%-89.6%$16.59MN/A-0.2839CARMCarisma Therapeutics3.0509 of 5 stars$0.40-2.0%$1.93+387.3%-68.9%$16.51M$19.96M-0.2520Positive NewsGap Down Related Companies and Tools Related Companies Longeveron Alternatives Cingulate Alternatives BioLineRx Alternatives ProPhase Labs Alternatives Marker Therapeutics Alternatives Reviva Pharmaceuticals Alternatives Mannatech Alternatives Lipocine Alternatives Q32 Bio Alternatives Carisma Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MYNZ) was last updated on 7/17/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredTurn $1K into $50K with This DeFi GemI've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. Th...Crypto 101 Media | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mainz Biomed NV Please log in to your account or sign up in order to add this asset to your watchlist. Share Mainz Biomed With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free MYNZ Stock Alerts